BITTERZ
1.11.2020 12:02:07 CET | Business Wire | Press release
Today (November 1), on behalf of Bitterz LLC (Hinds Building, Kingstown, St. Vincent and the Grenadines), we are pleased to announce that our global crypto exchange Bitterz in Japan will start to provide services to our customers in China, Hong Kong and Taiwan.
To celebrate the grand opening, we are currently offering $50 worth of bitcoins to all customers who open a new account (free of charge).
We hope that you will enjoy the experience of trading with our Japanese crypto exchange with these bitcoins.
Bitterz Official Website
https://bitterz.com/refs/top/10457
▪ Main features of Bitterz
1. A safe environment to continue trading
Bitterz is a completely Japanese crypto exchange, which is rare among global exchanges.
We offer a trading environment suitable for accumulating wealth, with a leverage of 200 times at most, a zero-cut system, and a reliable support system.
2. All the developers are Japanese
Bitterz's system development team is all Japanese and was formerly a group of engineers from a large, privately held company.
3. MT5: a specialized tool in cryptocurrency
With the fast response of MT5, we have achieved a stress-free trading environment.
You won't miss the trading timing even in the rapidly changing cryptocurrency market.
4. A highly secured trading environment
We have 24-hour-monitoring for dealing and security, a cold wallet to protect your holdings, and a two-step authentication system to prevent unauthorized logins, creating a highly secure trading environment.
Your cryptocurrency holdings are insured; with a multi-sig cold wallet, your holdings can only be transferred under multiple administrators’ approval.
Most of your holdings will be managed in the cold wallet, as we plan to store several days of withdrawals in the hot wallet.
5. Reliable support system
We offer the fastest support in the industry with native staffs from China and Taiwan to provide you with a secure trading environment.
6. Demo account for trading experience
You can experience cryptocurrency trading in the same environment as real trading without using your own money.
This is a great option for those who want a risk-free trading experience and who want to see how easy it is to use the tools in advance.
7. A reassuring zero-cut system
We have adopted a zero-cut system, where even in case of unexpected loss, there is no additional deposit in excess of your holdings, so you can trade proactively without worries.
8. Withdrawal (transfer) fees are practically free forever
There are many exchanges that don't charge a withdrawal (transfer) fee, but most of them require you to pay a mining fee.
Of course, we will never charge you a fee for withdrawal.
In addition, in order not to burden our clients with mining fees, we pay you back with MT5 bonus credit, which makes withdrawal (transfer) fees practically free.
9. Enrichment of campaigns
We aim to provide some kind of campaign at all times throughout the year.
Now, to celebrate the grand opening, we are currently offering $50 worth of bitcoins to all customers who open a new account (free of charge).
For more information, please visit the official website below.
Bitterz Official Website
https://bitterz.com/refs/top/10457
View source version on businesswire.com: https://www.businesswire.com/news/home/20201101005003/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom